# Collegium Pharmaceutical, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Collegium Pharmaceutical, Inc).

## Overview

Collegium Pharmaceutical, Inc. is a U.S.-based specialty pharmaceutical company focused on commercializing branded products for pain, attention deficit hyperactivity disorder (ADHD), and opioid-induced constipation. Its portfolio includes Xtampza ER, Belbuca, Jornay PM, the Nucynta Products, and Symproic, all sold primarily in the United States. The company’s business model depends on maintaining access to prescribers, payors, and a concentrated wholesale distribution network while managing the regulatory and reputational complexity of opioid and stimulant therapies. Collegium also relies heavily on third-party manufacturing and limited-source active pharmaceutical ingredient supply, which makes supply continuity a central part of its operating model.

## Products & services

• Xtampza ER extended-release oxycodone for chronic pain
• Belbuca buccal film for chronic pain management
• Jornay PM delayed-release ADHD treatment
• Nucynta Products (tapentadol) pain portfolio
• Symproic for opioid-induced constipation
• U.S. commercial sales and market-access support

- **Pain portfolio** (70%) — Branded opioid and pain-management products including Xtampza ER, Belbuca, and the Nucynta Products.
- **ADHD portfolio** (20%) — Jornay PM, a branded stimulant therapy marketed for pediatric and adolescent ADHD.
- **Opioid-induced constipation** (10%) — Symproic, an oral treatment for opioid-induced constipation in adult patients with chronic non-cancer pain.

- Xtampza ER extended-release oxycodone for chronic pain
- Belbuca buccal film for chronic pain management
- Jornay PM delayed-release ADHD treatment
- Nucynta Products (tapentadol) pain portfolio
- Symproic for opioid-induced constipation
- U.S. commercial sales and market-access support

## Customers

Collegium sells primarily through wholesale pharmaceutical distributors, which then supply retail pharmacies, managed care organizations, and government channels. Its pain portfolio is marketed to pain specialists and other prescribers of branded extended-release opioids, while Jornay PM is targeted to clinicians who write pediatric and adolescent extended-release stimulant prescriptions. The company also relies on market-access teams to secure formulary placement and negotiate with payors, because reimbursement strongly influences uptake in branded pharmaceuticals. End customers ultimately include patients treated for chronic pain, ADHD, and opioid-induced constipation, but the immediate buying decision is driven by distributors, payors, and prescribing physicians.

- **Wholesale pharmaceutical distributors** (primary) — Buy product inventory in bulk and distribute it to pharmacies and other channels; they are the key commercial gatekeepers for U.S. product access.
- **Pain specialists and chronic pain prescribers** (primary) — Prescribe Xtampza ER, Belbuca, and Nucynta Products based on efficacy, dosing convenience, and abuse-deterrence profile.
- **ADHD prescribers** (primary) — Prescribe Jornay PM for pediatric and adolescent ADHD patients, valuing differentiated release profile and clinical fit.
- **Managed care and payor organizations** (secondary) — Influence access through formulary approval, rebates, and contracting, which affect net pricing and volume.
- **Retail pharmacies and institutional end users** (secondary) — Receive products from wholesalers and dispense them to patients in retail, hospital, clinic, nursing home, and mail-order settings.

- Wholesale pharmaceutical distributors that purchase inventory for downstream pharmacy distribution
- Retail pharmacies that dispense the products to patients
- Managed care organizations that influence formulary access and reimbursement
- Pain specialists and other prescribers of branded opioid therapies
- Pediatric and adolescent ADHD prescribers for Jornay PM
- Government agencies and institutional customers in the U.S. channel

## Geography

Collegium’s business is overwhelmingly concentrated in the United States, where it commercializes all of its core products and maintains its sales forces and market-access organization. The company’s pain sales force calls on about 10,000 health care professionals, and its ADHD sales force calls on about 21,000 health care professionals, both within the U.S. market. Manufacturing is also U.S.-based but outsourced to third-party partners in Wisconsin, Pennsylvania, Minnesota, Ohio, and previously Puerto Rico for certain packaging activities. This geographic concentration means the company is exposed to U.S. prescription trends, FDA and state-level opioid regulation, and domestic wholesaler consolidation rather than broad international demand diversification.

- Revenue is concentrated in the United States, where all core products are commercialized
- Sales and marketing are organized around U.S. pain and ADHD prescriber networks
- Manufacturing and packaging are outsourced to U.S. third-party sites in Wisconsin, Pennsylvania, Minnesota, and Ohio
- Prior packaging work for Jornay PM was previously performed in Puerto Rico before shifting in 2026
- U.S. opioid policy, state taxes, and prescription limits are material operating risks
- Wholesaler consolidation in the U.S. affects pricing power and channel access

## Strategy

Collegium’s strategy is centered on defending and expanding its branded pain and ADHD franchises through differentiated product positioning, field sales execution, and payor access. The company emphasizes product attributes such as dosing convenience, safety, and abuse-deterrence for pain therapies, while educating clinicians on the risks associated with opioids and stimulants. It also seeks to improve formulary coverage and contracting through a dedicated market-access team, which is important because reimbursement can materially affect prescription volume. On the supply side, the company is working through manufacturing transitions and third-party production arrangements to support continuity and future growth.

- **Defend and grow the pain portfolio** (short-term) — Pain products remain the core revenue engine, so maintaining prescriber share and access is essential to offset competition from branded, generic, and non-opioid alternatives.
- **Expand Jornay PM adoption** (medium-term) — Jornay PM adds diversification into ADHD and can reduce dependence on the pain franchise if commercial execution improves.
- **Strengthen market access and payer contracting** (short-term) — Net revenue depends on rebates, chargebacks, and formulary placement, making access management central to volume and pricing realization.
- **Secure manufacturing and API supply continuity** (medium-term) — Limited-source APIs and outsourced manufacturing create supply risk that can interrupt commercialization if not managed tightly.

- Expand awareness of differentiated product features among prescribers
- Maintain strong formulary access through payor contracting and market access
- Use dedicated sales forces for pain and ADHD to target high-prescribing clinicians
- Support product continuity through third-party manufacturing and supply agreements
- Manage opioid-specific regulatory and reputational issues through clinician education
- Preserve cash and debt capacity while funding commercialization and product obligations

## Risks

Collegium faces concentrated commercial risk because a significant share of shipments goes through only a few wholesale distributors, and any disruption or loss of those accounts could materially affect sales. The company also depends on sole-source or limited-source API suppliers, so manufacturing interruptions, quality issues, or supply-chain disruptions could quickly constrain product availability. Its portfolio is exposed to intense competition from branded, generic, and non-opioid alternatives, while opioid and stimulant products face additional regulatory, pricing, and reputational pressure. Debt service, royalty obligations, and contingent payments add financial risk, and the company’s profitability depends on sustaining commercial performance across a relatively small number of products.

- **Wholesale distributor concentration** [high] — A significant percentage of shipments go to three wholesale pharmaceutical distributors, so account loss or reduced purchases would directly affect revenue and bargaining power.
- **API supply dependence** [high] — The company relies on a sole supplier or limited number of suppliers for active pharmaceutical ingredients, making it vulnerable to production failures and supply disruptions.
- **Competitive pressure in pain and ADHD** [medium] — Products compete against branded, generic, and non-opioid alternatives, which can reduce prescriptions and force pricing concessions.
- **Opioid regulatory and litigation environment** [high] — State and federal measures can impose taxes, take-back funding, prescribing limits, and compliance burdens on opioid manufacturers.
- **Debt and refinancing risk** [medium] — Substantial indebtedness and convertible notes require ongoing cash generation and may constrain capital allocation.

- Concentration in a small number of wholesale distributors can amplify revenue volatility
- Sole-source or limited-source API supply creates manufacturing and stock-out risk
- Competition from generic opioids, stimulants, and non-opioid pain therapies can pressure share
- Opioid-specific regulation can raise compliance costs and limit prescribing
- Wholesaler consolidation can increase pricing pressure and weaken negotiating leverage
- Debt and contingent obligations reduce financial flexibility

## Accounting

Collegium’s revenue recognition is highly judgmental because product sales are recorded at delivery net of estimated chargebacks, rebates, sales incentives, distribution fees, and returns. That means reported revenue can move materially with changes in payer mix, wholesaler purchasing patterns, and settlement activity, rather than just unit volume. The company also carries significant intangible assets from acquisitions, so amortization and potential impairment are important to understanding gross margin and earnings quality. In addition, contingent consideration, royalty obligations, deferred royalty arrangements, and tax valuation allowances require ongoing estimates that can create volatility in reported results.

- **Net revenue reserves** — Can materially shift quarterly revenue and margins
- **Intangible asset amortization** — Large impact on gross margin
- **Goodwill and intangible impairment** — Potential non-cash write-downs
- **Contingent consideration and royalty liabilities** — Can create earnings volatility

- Revenue is recognized on delivery net of estimated rebates, chargebacks, incentives, and returns
- Gross-to-net estimates can materially change reported product revenue period to period
- Acquired intangible asset amortization is a major component of cost of product revenues
- Goodwill and intangible asset impairment risk is important after acquisitions
- Contingent consideration and royalty obligations require fair value and estimate updates
- Inventory valuation and unsalable product reserves affect cost of sales

---

*Last updated: 2026-08-11T04:46:26.708814+00:00*